×
About 5,110 results

Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients
https://clinicaltrials.gov/ct2/show/NCT04524507

Dec 3rd, 2021 - This randomized, double-blinded, phase 2 trial will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with less than 8 days of symptoms. Eligible participants will receive institutional-guided standard-of-care (SOC) and ABO-compatible convalescent COVID-19 plasma (CCP). The CCP units will be tested for the presence of anti-SARS-CoV-2 antibodies and p...

Sirolimus in COVID-19 Phase 1
https://clinicaltrials.gov/ct2/show/NCT04371640

Dec 3rd, 2021 - This is a double-blinded, two-arm, randomized, placebo controlled study comparing the virological efficacy of add-on sirolimus with standard care to placebo and standard care. Virological efficacy is defined as the change from baseline to day 7 in SARS-CoV-2 viral burden measured by quantitative real-time polymerase chain reaction.

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
https://clinicaltrials.gov/ct2/show/NCT04283461

Dec 3rd, 2021 - This is a phase I, open-label, dose-ranging clinical trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based va...

NCI COVID-19 in Cancer Patients, NCCAPS Study
https://clinicaltrials.gov/ct2/show/NCT04387656

Dec 2nd, 2021 - PRIMARY OBJECTIVES: I. Characterize patient factors, such as pre-existing comorbidities, cancer type and treatment, and demographic factors, associated with short- and long-term outcomes of coronavirus 2019 (COVID-19), including symptoms, severity, and fatality, in adult and pediatric cancer patients undergoing treatment. II. Describe cancer treatment modifications made in response to COVID-19 ...

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
https://clinicaltrials.gov/ct2/show/NCT04374149

Dec 2nd, 2021 - A virally mediated pandemic of 2020 is linked to a novel Beta Coronavirus (COVID-19) sharing subgenus classification with the severe acute respiratory syndrome (SARS) virus. The predominant modes of transmission are respiratory aerosolization and contaminated surface contact. COVID-19 infection is characterized by a wide range of severity and disease manifestations from asymptomatic to respirat...

Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against the Virus That Cause COVID-19, Know as Severe Acute Respiratoy Syndrome Coronavirus 2 (SA...
https://clinicaltrials.gov/ct2/show/NCT05142553

Dec 2nd, 2021 - The study population includes 1075 healthy adults aged above 18 years old who have received two doses of the Comirnaty vaccine, and are at least 182 days and less than 365 days after their second dose will be randomly assigned to two treatment arms. In each arm, volunteers will be randomized in a ratio Test vaccine:Comirnaty of 2:1. Each participant will receive one booster immunisation and wil...

Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]
https://clinicaltrials.gov/ct2/show/NCT05142319

Dec 2nd, 2021 - ICOVID-19 vaccination programs worldwide have so far focused on raising population immunity through the primary COVID-19 vaccine series. In Singapore two mRNA vaccines developed by Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), have been granted interim authorisation by Health Science Authority (HSA) under the pandemic special access route (PSAR). Some other COVID-19 vaccines are authorise...

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
https://clinicaltrials.gov/ct2/show/NCT04569786

Dec 2nd, 2021 - The primary objectives of this study is to evaluate the safety and tolerability of V590 versus placebo and to assess the immunogenicity of V590 on Day 28. The primary hypothesis is that at least one well-tolerated dose of V590 increases the geometric mean titers (GMTs) of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike serum neutralizing antibody, as measured by plaque r...

Efforts Needed to Evaluate How CAR T-Cell Therapy Recipients Respond to COVID-19 Vaccination
https://www.onclive.com/view/efforts-needed-to-evaluate-how-car-t-cell-therapy-recipients-respond-to-covid-19-vaccination

Dec 1st, 2021 - Although CAR T-cell therapy have resulted in unprecedented response rates in patients with hematologic malignancies, the modality comes with distinctive toxicities and infection risks that may impact the effectiveness of COVID-19 vaccines, according to Muhammad Bilal Abid, MD, who added that more data are needed to better understand how to protect this vulnerable population amidst the pandemic....

ACTIV-2: A Study for Outpatients With COVID-19
https://clinicaltrials.gov/ct2/show/NCT04518410

Dec 1st, 2021 - This is a master protocol to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression. The study includes both infused and non-infused agents and is a randomized controlled platform that allows agents to be added and dropped during the course ...

Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant
https://clinicaltrials.gov/ct2/show/NCT05075928

Dec 1st, 2021 - SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection called COVID19. A large proportion of patients, in particular in severe forms, present with thrombotic manifestations (DVT, EP, stroke, thrombosis of dialysis circuits, etc.). A significant proportion is also a carrier of circulating anticoagulant (ACC or LA), making it possible to suggest a diagnosis o...

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (C...
https://clinicaltrials.gov/ct2/show/NCT05119855

Dec 1st, 2021 - The primary hypothesis is that concomitant administration in adolescents of the first doses of 9vHPV vaccine and mRNA-1273 vaccine induces noninferior geometric mean titers (GMTs) of antibodies to each of the 9vHPV vaccine types 4 weeks postdose 2 of 9vHPV vaccine AND noninferior geometric mean concentrations (GMCs) of SARS-CoV-2 spike protein-specific binding antibody at 4 weeks Postdose 2 of ...

Transfusion and COVID-19
https://clinicaltrials.gov/ct2/show/NCT05075915

Dec 1st, 2021 - Alsace was particularly and early on affected by SARS-CoV-2 and quickly implemented a reduction in scheduled admissions and non-urgent surgical interventions, making it possible to reduce requests for labile blood products linked to non-urgent surgical procedures. as has been reported in the literature; the population containment measures also led to a major reduction in traffic - and consequen...

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19
https://clinicaltrials.gov/ct2/show/NCT04895449

Nov 30th, 2021 - The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized SARS-CoV-2 spike protein (S). This will be a phase Ib multi-center study in approximately 60 adults aged 18-64 years. Part A (N=24 seronegative subjects). Each participant will receive two single injections, 28 days apart. low dose ≥ 1 x 10e7 IU (N=8) middle dose ≥ 5 x 10e7 IU (N=8) high dose ≥ 1 x 10e8 I...

Booster Vaccination Against COVID-19
https://clinicaltrials.gov/ct2/show/NCT04979949

Nov 30th, 2021 - To determine the safety and immunogenicity of booster doses of vaccine against SARS-CoV2 after a minimum of 90 days and a maximum of 270 days after the 2nd dose of a homologous 2 dose primary regimen. It is planned to recruit 111 subjects for 2 vaccines (Turkovac and CoronaVac). There will be a total of 222 subjects.

Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001
https://clinicaltrials.gov/ct2/show/NCT05137444

Nov 30th, 2021 - The phase Ⅱ trial adopts a randomized, double-blind, placebo-controlled design to evaluate the immunogenicity and safety profile of LYB001 in healthy adults aged 18 years and older. This Phase III study adopts a single-arm, open-label design to evaluate the expanded safety of LYB001 in healthy subjects 18 years of age and older. The study vaccine will be administered IM at upper arm deltoid as ...

Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04382053

Nov 30th, 2021 - This was a Phase II, randomized, controlled, open label multi-center study to assess the efficacy and safety of DFV890 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function. The study consisted of four distinct study periods: Screening / Baseline visit (Day -1 to 1): lasted up to a maximum of 24 hours and comprised a screening / baseline ass...

Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
https://clinicaltrials.gov/ct2/show/NCT05047783

Nov 30th, 2021 - The primary objective is to evaluate the virologic efficacy of masitinib plus Best Supportive Care (BSC), with respect to placebo plus BSC in reducing viral shedding of SARS-CoV-2 in patients with symptomatic mild to moderate COVID-19. Patients will be randomized into one of the following treatment groups (all patients will receive BSC): Masitinib 3.0 mg/kg/day for 10 days versus corresponding ...

Systematic Genomic and Clinical Analysis of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfections and Recurrences Involving the Same Strain
https://wwwnc.cdc.gov/eid/article/28/1/21-1952_article

Nov 29th, 2021 - Since the first description of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection on August 24, 2020, in a patient from Hong Kong (1) who acquired a second infection after having traveled to Europe, several reports have described other individual reinfection cases in different countries. These cases suggest the lack of a common reinfection pattern, with a variety of inte...

Reliability of Standardized Protocol of Ultrasound of the Lungs in Prediction of Severity of Covid-19 Infection
https://clinicaltrials.gov/ct2/show/NCT04513210

Nov 29th, 2021 - Covid-19 pneumonia became the worldwide, serious health problem, affecting nearly 20 million people and causing nearly one million deaths. The health systems of many countries are overwhelmed with the increased need of medical care, of the number of available hospital beds, intensive care beds and ventilators. The proper management of available resources becomes now critical. Ultrasound can rel...